Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BHV-1300 in Graves' Disease
NCT06980649Phase 1Recruiting
- Sponsor
- Biohaven Ltd.
- Start
- Aug 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of BHV-1300 in Graves' disease, sponsored by Biohaven Ltd. Primary endpoints: Number of participants with Serious Adverse Events (SAEs), Adverse Events leading to discontinuation, and deaths at 52 weeks and Number of participants with Grade 3-4 (CTCAE/DAIDS) treatment-emergent laboratory abnormalities at 52 weeks. Started Aug 2025; status: recruiting.
02
Drugs
BHV-1300
03
Conditions
Graves' disease
Beyond the preview
Go deeper on NCT06980649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06980649.